Advancing MBTA Immunotherapy to Treat Cancer
We are bringing to life an advanced immunotherapy approach that has the potential to change lives for patients around the world.
More than 80% treatment success rate: The exceptional effectiveness of this therapy, verified through standard procedures in mouse models of melanoma, sarcoma, pancreatic adenocarcinoma, colorectal carcinoma, pheochromocytoma, breast cancer, and glioblastomas, predicts promising results for human medicine as well.
The mission of the Cancer Immunotherapy Endowment Fund is direct and clear: Our goal is to bring MBTA cancer immunotherapy to clinical trials and ultimately into the hands of physicians.
Clinically driven mission
Our goal is to bring MBTA cancer immunotherapy to clinical trials and ultimately into physicians’ hands.
Peer-reviewed evidence
More than 80% treatment success in validated mouse models across multiple cancer types.
Transparent funding
Donations support pre-clinical to clinical translation, reported regularly for donors and partners.
Your support accelerates an evidence-based therapy into the clinic.
⚠️ Please note: MBTA therapy cannot be used in clinical practice prior to or during the clinical trial phase.